Need more? Try out  Advanced Search (20+ criteria)»

logo

Last Update

This profile was last updated on 6/17/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Gary Frashier?

Gary E. Frashier

Managing Partner

Targeted Technology

HQ Phone:  (210) 558-8896

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Targeted Technology

18618 Tuscany Stone Drive Suite 100

San Antonio, Texas,78258

United States

Company Description

About Targeted Technology: Targeted Technology is a San Antonio-based venture capital firm which focuses on early stage investments in companies that can advance ground breaking or disruptive technologies to significantly improve the practice of medicine and p...more

Background Information

Employment History

Contributor

PR Newswire


Chairman and Chief Executive Officer

OSI Pharmaceuticals , Inc.


Executive Vice President

Millipore Corporation


Chairman and Chief Executive Officer

Continental Water Systems Pty Ltd


President and Chief Executive Officer

OSIP


Affiliations

BioMed SA

Board Member


Achillion Pharmaceuticals Inc

Board Member


ViroXis Corporation

Board Member


Metric Medical Devices Inc

Board Member


Santalis Corporation

Advisor


StemBioSys , Inc.

Board Member


Management & Associates Inc

President and Principal


Boston Life Sciences , Inc.

Board Member


Sloan

Fellow


Inex Pharmaceuticals Corporation

Board Member


Texas Tech University

Distinguished Engineer


Xeris Pharmaceuticals , Inc.

Board Member


MERRIMACK PHARMACEUTICALS INC

Founder


America Stem Cell , Inc.

Business Advisory Board Member


Massachusetts Institute of Technology

Member, Advisory Boards


Young Presidents' Organization Inc

Member


Education

B.S

Chemical Engineering

Texas Tech


M.B.A.

Massachusetts Institute


M.S.

Management

M.I.T


Web References(117 Total References)


Targeted Technology | Alan Dean

www.targetedtech.com [cached]

Gary Frashier, MBA, PE


Technical briefings, tours highlight 69th SwRI annual meeting | SwRI

www.swri.org [cached]

New advisory trustees serving the 2016-2019 term include John Barton of Texas A&M University, Dr. Daniel Baker of the University of Colorado Laboratory of Atmospheric and Space Physics, George Cotter of Isologic, and Gary Frashier of Targeted Technology Funds.


Targeted Technology | Gary Frashier

www.rt-designs.com [cached]

Gary Frashier, MBA, PE
Targeted Technology | Gary Frashier Targeted Technology Gary Frashier, MBA, PE Gary Frashier Managing Partner Gary Frashier brings extensive experience to the Fund, having served as a Chief Executive Officer for over 24 years in life science and specialty chemicals, and has over 17 years of experience in international operations. Gary served as the CEO and Chairman of OSI Pharmaceuticals, Inc, and it was during his nine year tenure at OSI that the leading genetic-based cancer drug, "Tarceva", was discovered and developed through proof-of-concept human clinical trials. Tarceva is now sold globally by Roche, Genentech and Astellas for the treatment of many solid tumors with sales of over $1.9 Billion per year. OSI was acquired by Astellas in 2010 for a price of $4 Billion. Prior to OSI, Gary served as Executive Vice President of Millipore Corporation and as President of their International Operations. When Millipore acquired Waters Corporation, he served as President and CEO of their Waters Chromatography subsidiary. Prior to this, he joined Genex Corporation, which discovered, developed and patented the first single-chain antibodies. Gary financed over $250 Million in capital for his companies from a combination of equity fundings and other sources, and is a Strategic Partner in SV Life Sciences, a major Boston venture capital company. Gary has served as a founder of several life sciences companies, including Merrimack Pharmaceuticals, Eutropics, America Stem Cell, and Apex BioVentures Acquisition Corporation. He has also served on the Board of Directors of Maxim Pharma, Merrimack Pharma, Tekmira, Exegenics, Aderis Pharma, and Alseres Pharma, and is currently on the Boards of Achillion Pharmaceuticals, (NASDAQ:ACHN), ViroXis Corporation, StemBioSys and Metric Medical. Gary has a BS in Chemical Engineering from Texas Tech University and an MS from the Massachusetts Institute of Technology in Management (Alfred P. Sloan Fellow).


Targeted Technology | Alan Dean

www.rt-designs.com [cached]

Gary Frashier, MBA, PE
With directors Robert Langer (MIT), Henry Brem (John's Hopkins) and Gary Frashier (OSI), Peter and his management team negotiated a Special Protocol Assessment with the US FDA that reduced Altropane's Phase 3 registration trial requirements by 6 years and $130 million while extending the company's intellectual property expiry from 2013 to 2028.


Leadership Items

www.biomedsa.org [cached]

Gary Frashier, M.B.A., P.E., Managing Partner
Targeted Technology (Venture Capital/Investors)


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory